376 Overcoming tumor heterogeneity – Clinical trial assays to prospectively assign patients customized multiplexed TCR-T cell therapy in Phase 1
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |